Drug Trial Radar · NCT07016074
Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Nov 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- University of MichiganAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot study is designed to test the logistics and recruitment of a trial testing the benefit of sodium nitrate in the prevention of contrast-associated kidney injury in a group of patients at high-risk.
Conditions
- Kidney Injury, Acute
Interventions
Sodium NitrateDrug
The study drug is sodium nitrate capsule at a dose of 12mmol of nitrate. This medication will be given orally 1-8 hours before the planned contrast administration and then once per day for a total of four doses.
PlaceboDrug
The placebo control medication will be a capsule filled with lactose that will be taken in the same manner and schedule as the sodium nitrate capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of participants receiving the first dose of blinded study drug within 1-8 hours prior to contrast exposureTime frame: Approximately 34 days
- Percent of participants completing full course of 4 doses of blinded study drugTime frame: Approximately 34 days
- Percent of participants with 48-hour basic metabolic panel collected between 36-108 hours of contrast exposureTime frame: Approximately 34 days
- Percent of participants who had completion of clinical outcome monitoring at 30-day follow-up interviewTime frame: Approximately 34 days
- Percent of participants recruited to the trial for undergoing coronary angiogramTime frame: Approximately 34 days
- Percent of participants recruited to the trial for undergoing a contrast-enhanced CT scanTime frame: Approximately 34 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Michigan
Ann Arbor, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.